Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Wedbush
7 Articles
7 Articles
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Wedbush
Wedbush reduced their price target on shares of Xenon Pharmaceuticals from $71.00 to $55.00 and set an "outperform" rating on the stock in a research note on Friday.
Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade) (NASDAQ:XENE)
This article was written by Follow With a background as a RN, I analyze healthcare-related stocks by evaluating clinical data, treatment guidelines, and market dynamics. After completing my MBA, I expanded into tech, where I deploy DCF modeling to uncover implicit market expectations for growth and cash generation. My writing is influenced by books such as “Superforecasting” and “Fooled by Randomness.” Analyst’s Disclosure: I/we have no stock…
Is Xenon Pharmaceuticals (XENE) Stock a Buy After Its Worst Drop in Nearly a Decade?
TLDR Xenon submitted a New Drug Application for azetukalner in focal seizures, marking a potential first commercial product The company paused new patient enrollment in major depressive disorder and bipolar depression trials due to neuropsychiatric adverse events XENE stock dropped 25% to $42.84 in...
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium






